Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue (Thymosin Fraction 5) by Dr. Allan Goldstein at the George Washington University School of Medicine. It acts through Toll-like receptors (TLR2, TLR9) to promote dendritic cell maturation, enhance MHC class I expression, and stimulate T-cell differentiation from CD34+ hematopoietic progenitors. It has been approved as a pharmaceutical agent in over 35 countries for various clinical applications, making it one of the most clinically validated peptides in existence.

The thymus gland — most active during childhood, then gradually involuting with age — is where T-cells undergo positive and negative selection, learning to distinguish self from non-self. This organ functions as an immune school, where each T-cell is educated, tested, and either graduated or eliminated. Thymosin Alpha-1 is the molecular instructor in this process, facilitating the education that gives the adaptive immune system its extraordinary specificity and memory.

At 99%+ purity (HPLC verified), our Thymosin Alpha-1 is formulated for research into thymic peptide biology, Toll-like receptor signaling, and T-cell differentiation pathways.